Insights into mucopolysaccharidosis I from the structure and action of α-L-iduronidase

Nature Chemical Biology

Volumn 9, Issue 11, 2013, Pages 739-745

  Bie, Haiying ^a   Yin, Jiang ^a   He, Xu ^b   Kermode, Allison R ^b   Goddard Borger, Ethan D ^c   Withers, Stephen G ^c   James, Michael N G ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINE; FIBRONECTIN; IDURONIC ACID; LEVO IDURONIDASE;

ARABIDOPSIS THALIANA; ARTICLE; BINDING SITE; COMPARATIVE STUDY; CONFORMATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; GLYCOSYLATION; HURLER SYNDROME; HYDROGEN BOND; MISSENSE MUTATION; MUTANT; NONHUMAN; NUCLEOPHILICITY; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ALIGNMENT;

ARABIDOPSIS THALIANA;

EID: 84886594873     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1357     Document Type: Article

References (50)

1. Clarke, L.A. The mucopolysaccharidoses: A success of molecular medicine. Expert Rev. Mol. Med. 10, e1 (2008).
2. Roubicek, M., Gehler, J. & Spranger, J. The clinical spectrum of a-l-iduronidase deficiency. Am. J. Med. Genet. 20, 471-481 (1985).
3. Valenzano, K.J. et al. Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders. Assay Drug Dev. Technol. 9, 213-235 (2011).
4. Tropak, M.B. et al. Identification of pharmacological chaperones for Gaucher disease and characterization of their effects on b-glucocerebrosidase by hydrogen/deuterium exchange mass spectrometry. ChemBioChem 9, 2650-2662 (2008).
5. Yu, Z., Sawkar, A.R. & Kelly, J.W. Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J. 274, 4944-4950 (2007).
6. Neufeld, E.F. & Muenzer, J. The Metabolic and Molecular Bases of Inherited Disease Vol. III (eds. Scriver, C.R. et al.) 3421-3452 (McGraw-Hill, New York, 2001).
7. Terlato, N.J. & Cox, G.F. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet. Med. 5, 286-294 (2003).
8. Nieman, C.E. et al. Family 39 a-l-iduronidases and b-d-xylosidases react through similar glycosyl-enzyme intermediates: Identification of the human iduronidase nucleophile. Biochemistry 42, 8054-8065 (2003).
9. Yang, J.K. et al. Crystal structure of b-d-xylosidase from Thermoanaerobacterium saccharolyticum, a family 39 glycoside hydrolase. J. Mol. Biol. 335, 155-165 (2004).
10. Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J. Basic local alignment search tool. J. Mol. Biol. 215, 403-410 (1990).
11. Rempel, B.P., Clarke, L.A. & Withers, S.G. A homology model for human a-liduronidase: Insights into human disease. Mol. Genet. Metab. 85, 28-37 (2005).
12. Zhao, K.W., Faull, K.F., Kakkis, E.D. & Neufeld, E.F. Carbohydrate structures of recombinant human a-l-iduronidase secreted by Chinese hamster ovary cells. J. Biol. Chem. 272, 22758-22765 (1997).
13. He, X. et al. Characterization and downstream mannose phosphorylation of human recombinant alpha-L-iduronidase produced in Arabidopsis complex glycan-deficient (cgl) seeds. Plant Biotechnol J. doi:10.1111/pbi.12096 (31 July 2013).
14. Vocadlo, D.J., MacKenzie, L.F., He, S., Zeikus, G.J. & Withers, S.G. Identification of glu-277 as the catalytic nucleophile of Thermoanaerobacterium saccharolyticum b-xylosidase using electrospray MS. Biochem. J. 335, 449-455 (1998).
15. Armand, S. et al. Stereochemical course and reaction products of the action of b-xylosidase from Thermoanaerobacterium saccharolyticum strain B6A-RI. Eur. J. Biochem. 236, 706-713 (1996).
16. Rostkowski, M., Olsson, M.H., Sondergaard, C.R. & Jensen, J.H. Graphical analysis of pH-dependent properties of proteins predicted using PROPKA. BMC Struct. Biol. 11, 6 (2011).
17. Maita, N. et al. Human a-l-iduronidase uses its own N-glycan as a substratebinding and catalytic module. Proc. Natl. Acad. Sci. USA 110, 14628-14633 (2013).
18. Hopwood, J.J. & Muller, V. Diagnostic enzymology of a-l-iduronidase with special reference to a sulfated disaccharide derived from heparin. Clin. Sci. (Lond.) 62, 193-201 (1982).
19. Yogalingam, G. et al. Identification and molecular characterization of a-liduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Hum. Mutat. 24, 199-207 (2004).
20. Clements, P.R., Muller, V. & Hopwood, J.J. Human a-l-iduronidase. 2. Catalytic properties. Eur. J. Biochem. 152, 29-34 (1985).
21. Vocadlo, D.J., Davies, G.J., Laine, R. & Withers, S.G. Catalysis by hen egg-white lysozyme proceeds via a covalent intermediate. Nature 412, 835-838 (2001).
22. Davies, G.J., Planas, A. & Rovira, C. Conformational analyses of the reaction coordinate of glycosidases. Acc. Chem. Res. 45, 308-316 (2012).
23. Koshland, D.E. Stereochemistry and the mechanism of enzymatic reactions. Biol. Rev. Camb. Philos. Soc. 28, 416-436 (1953).
24. Heightman, T.D. & Vasella, A.T. Recent insights into inhibition, structure, and mechanism of configuration-retaining glycosidases. Angew. Chem. Int. Edn Engl. 38, 750-770 (1999).
25. Sabini, E. et al. Catalysis and specificity in enzymatic glycoside hydrolysis: A 2,5B conformation for the glycosyl-enzyme intermediate revealed by the structure of the Bacillus agaradhaerens family 11 xylanase. Chem. Biol. 6, 483-492 (1999).
26. Sidhu, G. et al. Sugar ring distortion in the glycosyl-enzyme intermediate of a family G/11 xylanase. Biochemistry 38, 5346-5354 (1999).
27. Matte, U. et al. Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol. Genet. Metab. 78, 37-43 (2003).
28. Alif, N. et al. Mucopolysaccharidosis type I: Characterization of a common mutation that causes Hurler syndrome in Moroccan subjects. Ann. Hum. Genet. 63, 9-16 (1999).
29. Laradi, S. et al. Mucopolysaccharidosis I: A-l-iduronidase mutations in three Tunisian families. J. Inherit. Metab. Dis. 28, 1019-1026 (2005).
30. Scott, H.S. et al. a-l-Iduronidase mutations (Q70X and P533R) associate with a severe Hurler phenotype. Hum. Mutat. 1, 333-339 (1992).
31. Bunge, S. et al. Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim. Biophys. Acta 1407, 249-256 (1998).
32. Bashyal, B.P., Chow, H.-F., Fellows, L.E. & Fleet, G.W.J. The synthesis of polyhydroxylated amino acids from glucuronolactone: Enantiospecific synthesis of 2S,3R,4R,5S-Trihydroxypipecolic acid, 2R,3R,4R,5S- Trihydroxypipecolic acid and 2R,3R,4R-dihydroxyproline. Tetrahedron 43, 415-422 (1987).
33. Downing, W.L. et al. Synthesis of enzymatically active human á-l-iduronidase in Arabidopsis cgl (complex glycan-deficient) seeds. Plant Biotechnol. J. 4, 169-181 (2006).
34. He, X. et al. Production of á-l-iduronidase in maize for the potential treatment of a human lysosomal storage disease. Nat. Commun. 3, 1062 (2012).
35. He, X. et al. Influence of an ER-retention signal on the N-glycosylation of recombinant human á-l-iduronidase generated in seeds of Arabidopsis. Plant Mol. Biol. 79, 157-169 (2012).
36. Ruth, L., Eisenberg, D. & Neufeld, E.F. á-l-iduronidase forms semi-crystalline spherulites with amyloid-like properties. Acta Crystallogr. D Biol. Crystallogr. 56, 524-528 (2000).
37. Kabsch, W. Xds. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
38. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326 (1997).
39. Adams, P.D. et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221 (2010).
40. Langer, G., Cohen, S.X., Lamzin, V.S. & Perrakis, A. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat. Protoc. 3, 1171-1179 (2008).
41. Emsley, P. & Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
42. Winn, M.D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
43. Murshudov, G.N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 67, 355-367 (2011).
44. Word, J.M., Lovell, S.C., Richardson, J.S. & Richardson, D.C. Asparagine and glutamine: Using hydrogen atom contacts in the choice of side-chain amide orientation. J. Mol. Biol. 285, 1735-1747 (1999).
45. McCoy, A.J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658-674 (2007).
46. Winn, M.D., Murshudov, G.N. & Papiz, M.Z. Macromolecular TLS refinement in REFMAC at moderate resolutions. Methods Enzymol. 374, 300-321 (2003).
47. Painter, J. & Merritt, E.A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-450 (2006).
48. Laskowski, R.A., Macarthur, M.W., Moss, D.S. & Thornton, J.M. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291 (1993).
49. Chakrabarty, R. et al. PSITE vectors for stable integration or transient expression of autofluorescent protein fusions in plants: Probing Nicotiana benthamiana-virus interactions. Mol. Plant Microbe Interact. 20, 740-750 (2007).
50. Babajani, G., Tropak, M.B., Mahuran, D.J. & Kermode, A.R. Pharmacological chaperones facilitate the post-ER transport of recombinant N370S mutant â-glucocerebrosidase in plant cells: Evidence that N370S is a folding mutant. Mol. Genet. Metab. 106, 323-329 (2012).